issues
October 2011
Download PDFTABLE OF CONTENTS
Karma in Clinical Trials:
Derek G. Hennecke, MBA, concludes his 6-part series on how not to blow the recovery!
Generic DDEP Sales & Prescription Performance 2010
Josef Bossart, PhD, in his previous discussion, examined the sales and prescription performance of branded DDEPs in 2010; this issue will look at how generic DDEPs performed in the same period.
Injectable Drug Delivery – Easing the Pain With Technology
Frost & Sullivan Analyst Debbie Toscano says innovation in injectable drug delivery system design is in a constant state of evolution as manufacturers strive to meet the ever-changing demand for safe, functional, and patient-friendly devices.
Recent Trends in Drug Discovery & Drug Solubility: A Novel Hybrid Particle-Engineering Approach to Solving the Insoluble
Gary G. Liversidge, PhD, indicates the NanOsmotic® technology offers a number of potential performance advantages over alternative technologies in the poorly water-soluble drug delivery space, including enhanced bioavailability, improved chemical and physical stability, higher drug loading, and the ability to achieve programmable release of drug for extended periods.
Nose-to-Brain Drug Delivery: A Review
Hardik K. Patel, MPharm; Rajnikant M. Suthar, MPharm; Sandip R. Patel, MPharm; et al believe that although nose-to-brain delivery may not completely replace conventional solid dosage form therapy, it could act in a synergistic way to offer a variety of options and strategies for better treating brain disorders and emergency situations.
Solid Dosage Forms for Biopharmaceutical Classification System Class II APIs
Garry Gwozdz, Robert Gwozdz, and Robert W. Lee, PhD, focus on formulation of nanoparticulates via milling as well as solid solutions, as these are two of the most widely applicable of the available technologies. Conversion of nanoparticulates into solid oral dosage forms are also discussed.
Fast-Tracking Time to Market in the Early Stages of Drug Development
Thomas Pointeaux, MS, and Julien Meissonnier examine how a global internal network of support services can provide an integrated project management offering that enables seamless coordination of dosage form development, analytical development/validation, clinical packaging, IMPD documentation, and final QP releases.
Ligand: Providing Solutions to the Solubility, Stability & Compatibility Issues in the Pharmaceutical Industry
Drug Development Executive: Matt Foehr, Executive Vice President & Chief Operating Officer of Ligand, discusses the Captisol-enabled technology and its significant role in the pharmaceutical marketplace of today and tomorrow.
Hot-Melt Extrusion Technology – A Versatile Tool for Drug Delivery
Pirthi Pal Singh, PhD; Paramjit Singh, PhD; and Sarabjit Singh, MPharm; summarize the principles, operations, and potential applications of HME in the pharmaceutical industry.
Enhanced Albumin Fusion Technology: Tailoring & Controlling the Pharmacokinetics of Therapeutic Drugs
Drug Development Executive: Thomas Videbæk, Executive Vice President of Novozymes BioBusiness, discusses the Novozymes’ vision and how it is helping customers develop novel drugs with improved PK properties.
DEPARTMENTS
Market News & Trends
Advanced Delivery Devices
The Challenges in Developing Today’s Pharmaceutical Drug Delivery Devices
Technology & Services Showcase
External Delivery
The Best Chewing Out I Ever Received
COVER
FEATURES
